On March 8, 2023, the National Medical Products Administration (NMPA) announced that it had recently granted conditional marketing authorization for Cumetinib Tablets, a Class 1 innovative drug filed by Shanghai Haihe Pharmaceutical Research and Development Co., Ltd. This drug is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition factor (MET) exon 14 skipping alterations.
Cumetinib exerts a selective inhibitory effect on c-Met kinase activity, which in turn suppresses the proliferation, migration and invasion of tumor cells. The launch of this drug offers a new therapeutic option for patients with locally advanced or metastatic NSCLC carrying MET exon 14 skipping alterations.
